News

Filter by:
  • 20240229_SCKCEN-Impact medical discharge on environment-Water treatment plant.jpg
    29 February '24

    SCK CEN sheds light on the long-term effects of radioisotopes in rivers and enhances protection for humans and nature

    New method for assessing the impact of medical radiopharmaceuticals on the environment

    When you receive a diagnosis or treatment involving medical radioisotopes in the hospital, a small amount of radioactivity ends up in the sewer after your restroom visit. But what if we use more of these medical substances in the future? Will the existing protective measures still be effective? Research conducted by SCK CEN, the Belgian Nuclear Research Center, provides a way to assess the safety of these discharges. As part of the European SINFONIA project, experts proactively investigated the potential long-term effects of hospital wastewater on the environment and human health. The result is a new methodology for more accurately assessing the possible impact on people, animals, and the environment. “This approach is particularly useful for predicting the impact of future new medications on the ecosystem and proactively adjusting regulations as needed,” emphasizes Jordi Vives i Batlle, an expert in impact studies at SCK CEN.

  • SCK CEN - Lancering Pantera (2022)
    13 February '24

    PanTera signs agreement with Bayer for the supply of actinium-225

    Agreement demonstrates PanTera’s unique ability to support the radionuclide therapeutics industry in bringing new cancer treatments to patients

    PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of alpha-emitting radioisotopes, today announces the signing of a capacity reservation agreement with Bayer for the supply of actinium-225 (225Ac) starting in the second half of 2024.

  • SCK CEN - Highlights 2022 (2023)
    04 February '24

    BR2 made every production second of 2023 count in the fight against cancer

    In a world where every minute counts in the race against cancer, our BR2 research reactor did not let a single second of production slip by in 2023. “We achieved 100% of the production days we announced. In short: 100% availability and reliability for patients,” said Steven Van Dyck, Director of BR2 at the nuclear research centre SCK CEN.